432 lines
105 KiB
Text
432 lines
105 KiB
Text
<!DOCTYPE html>
|
|
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" class="no-js no-jr">
|
|
<head>
|
|
<!-- For pinger, set start time and add meta elements. -->
|
|
<script type="text/javascript">var ncbi_startTime = new Date();</script>
|
|
|
|
<!-- Logger begin -->
|
|
<meta name="ncbi_db" content="books">
|
|
<meta name="ncbi_pdid" content="book-toc">
|
|
<meta name="ncbi_acc" content="NBK603289">
|
|
<meta name="ncbi_domain" content="niceng239er7">
|
|
<meta name="ncbi_report" content="reader">
|
|
<meta name="ncbi_type" content="fulltext">
|
|
<meta name="ncbi_objectid" content="">
|
|
<meta name="ncbi_pcid" content="/NBK603289/?report=reader">
|
|
<meta name="ncbi_pagename" content="Evidence review for monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis - NCBI Bookshelf">
|
|
<meta name="ncbi_bookparttype" content="toc">
|
|
<meta name="ncbi_app" content="bookshelf">
|
|
<!-- Logger end -->
|
|
|
|
<!--component id="Page" label="meta"/-->
|
|
<script type="text/javascript" src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.boots.min.js"> </script><title>Evidence review for monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis - NCBI Bookshelf</title>
|
|
<meta charset="utf-8">
|
|
<meta name="apple-mobile-web-app-capable" content="no">
|
|
<meta name="viewport" content="initial-scale=1,minimum-scale=1,maximum-scale=1,user-scalable=no">
|
|
<meta name="jr-col-layout" content="1">
|
|
<meta name="robots" content="INDEX,FOLLOW,NOARCHIVE,NOIMAGEINDEX">
|
|
<meta name="citation_title" content="Evidence review for monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis">
|
|
<meta name="citation_publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="citation_date" content="2024/03">
|
|
<meta name="citation_pmid" content="38691633">
|
|
<meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK603289/">
|
|
<meta name="citation_keywords" content="Vitamin B 12">
|
|
<meta name="citation_keywords" content="Vitamin B 12 Deficiency">
|
|
<meta name="citation_keywords" content="Aftercare">
|
|
<meta name="citation_keywords" content="Gastrointestinal Neoplasms">
|
|
<meta name="citation_keywords" content="Diagnosis">
|
|
<meta name="citation_keywords" content="Intrinsic Factor">
|
|
<meta name="citation_keywords" content="Anemia, Macrocytic">
|
|
<meta name="citation_keywords" content="Gastroscopy">
|
|
<meta name="citation_keywords" content="Adolescent">
|
|
<meta name="citation_keywords" content="Young Adult">
|
|
<meta name="citation_keywords" content="Adult">
|
|
<meta name="citation_keywords" content="Middle Aged">
|
|
<meta name="citation_keywords" content="Aged">
|
|
<meta name="citation_keywords" content="Aged, 80 and over">
|
|
<meta name="citation_keywords" content="Humans">
|
|
<meta name="citation_keywords" content="Review">
|
|
<link rel="schema.DC" href="http://purl.org/DC/elements/1.0/">
|
|
<meta name="DC.Title" content="Evidence review for monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis">
|
|
<meta name="DC.Type" content="Text">
|
|
<meta name="DC.Publisher" content="National Institute for Health and Care Excellence (NICE)">
|
|
<meta name="DC.Date" content="2024/03">
|
|
<meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK603289/">
|
|
<meta name="og:title" content="Evidence review for monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis">
|
|
<meta name="og:type" content="book">
|
|
<meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK603289/">
|
|
<meta name="og:site_name" content="NCBI Bookshelf">
|
|
<meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng239er7-lrg.png">
|
|
<meta name="twitter:card" content="summary">
|
|
<meta name="twitter:site" content="@ncbibooks">
|
|
<meta name="bk-non-canon-loc" content="/books/n/niceng239er7/toc/?report=reader">
|
|
<link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK603289/">
|
|
<link href="https://fonts.googleapis.com/css?family=Archivo+Narrow:400,700,400italic,700italic&subset=latin" rel="stylesheet" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/libs.min.css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/jatsreader/ptpmc_3.22/css/jr.min.css">
|
|
<meta name="format-detection" content="telephone=no">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books.min.css" type="text/css">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css//books_print.min.css" type="text/css" media="print">
|
|
<link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.26/css/books_reader.min.css" type="text/css">
|
|
<style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace} .first-line-outdent .bk_ref {display: inline} .body-content h2, .body-content .h2 {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list .graphic {display:inline-block !important} .temp-labeled-list img{width:100%}</style>
|
|
|
|
<link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico">
|
|
<meta name="ncbi_phid" content="CE8B8B567D6AEBC100000000011400E2.m_5">
|
|
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/css/3852956/3849091.css"></head>
|
|
<body>
|
|
<!-- Book content! -->
|
|
|
|
|
|
<div id="jr" data-jr-path="/corehtml/pmc/jatsreader/ptpmc_3.22/"><div class="jr-unsupported"><table class="modal"><tr><td><span class="attn inline-block"></span><br />Your browser does not support the NLM PubReader view.<br />Go to <a href="/pmc/about/pr-browsers/">this page</a> to see a list of supported browsers<br />or return to the <br /><a href="/books/NBK603289/?report=classic">regular view</a>.</td></tr></table></div><div id="jr-ui" class="hidden"><nav id="jr-head"><div class="flexh tb"><div id="jr-tb1"><a id="jr-links-sw" class="hidden" title="Links"><svg xmlns="http://www.w3.org/2000/svg" version="1.1" x="0px" y="0px" viewBox="0 0 70.6 85.3" style="enable-background:new 0 0 70.6 85.3;vertical-align:middle" xml:space="preserve" width="24" height="24">
|
|
<style type="text/css">.st0{fill:#939598;}</style>
|
|
<g>
|
|
<path class="st0" d="M36,0C12.8,2.2-22.4,14.6,19.6,32.5C40.7,41.4-30.6,14,35.9,9.8"></path>
|
|
<path class="st0" d="M34.5,85.3c23.2-2.2,58.4-14.6,16.4-32.5c-21.1-8.9,50.2,18.5-16.3,22.7"></path>
|
|
<path class="st0" d="M34.7,37.1c66.5-4.2-4.8-31.6,16.3-22.7c42.1,17.9,6.9,30.3-16.4,32.5h1.7c-66.2,4.4,4.8,31.6-16.3,22.7 c-42.1-17.9-6.9-30.3,16.4-32.5"></path>
|
|
</g>
|
|
</svg> Books</a></div><div class="jr-rhead f1 flexh"></div><div id="jr-tb2"><a id="jr-bkhelp-sw" class="btn wsprkl hidden" title="Help with NLM PubReader">?</a><a id="jr-help-sw" class="btn wsprkl hidden" title="Settings and typography in NLM PubReader"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 512 512" preserveAspectRatio="none"><path d="M462,283.742v-55.485l-29.981-10.662c-11.431-4.065-20.628-12.794-25.274-24.001 c-0.002-0.004-0.004-0.009-0.006-0.013c-4.659-11.235-4.333-23.918,0.889-34.903l13.653-28.724l-39.234-39.234l-28.72,13.652 c-10.979,5.219-23.68,5.546-34.908,0.889c-0.005-0.002-0.01-0.003-0.014-0.005c-11.215-4.65-19.933-13.834-24-25.273L283.741,50 h-55.484l-10.662,29.981c-4.065,11.431-12.794,20.627-24.001,25.274c-0.005,0.002-0.009,0.004-0.014,0.005 c-11.235,4.66-23.919,4.333-34.905-0.889l-28.723-13.653l-39.234,39.234l13.653,28.721c5.219,10.979,5.545,23.681,0.889,34.91 c-0.002,0.004-0.004,0.009-0.006,0.013c-4.649,11.214-13.834,19.931-25.271,23.998L50,228.257v55.485l29.98,10.661 c11.431,4.065,20.627,12.794,25.274,24c0.002,0.005,0.003,0.01,0.005,0.014c4.66,11.236,4.334,23.921-0.888,34.906l-13.654,28.723 l39.234,39.234l28.721-13.652c10.979-5.219,23.681-5.546,34.909-0.889c0.005,0.002,0.01,0.004,0.014,0.006 c11.214,4.649,19.93,13.833,23.998,25.271L228.257,462h55.484l10.595-29.79c4.103-11.538,12.908-20.824,24.216-25.525 c0.005-0.002,0.009-0.004,0.014-0.006c11.127-4.628,23.694-4.311,34.578,0.863l28.902,13.738l39.234-39.234l-13.66-28.737 c-5.214-10.969-5.539-23.659-0.886-34.877c0.002-0.005,0.004-0.009,0.006-0.014c4.654-11.225,13.848-19.949,25.297-24.021 L462,283.742z M256,331.546c-41.724,0-75.548-33.823-75.548-75.546s33.824-75.547,75.548-75.547 c41.723,0,75.546,33.824,75.546,75.547S297.723,331.546,256,331.546z"></path></svg></a><a id="jr-fip-sw" class="btn wsprkl hidden" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-cmap-sw" class="btn wsprkl hidden" title="Table of Contents"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,20h10v8H20V20zM36,20h44v8H36V20zM20,37.33h10v8H20V37.33zM36,37.33h44v8H36V37.33zM20,54.66h10v8H20V54.66zM36,54.66h44v8H36V54.66zM20,72h10v8 H20V72zM36,72h44v8H36V72z"></path></svg></a></div></div></nav><nav id="jr-dash" class="noselect"><nav id="jr-dash" class="noselect"><div id="jr-pi" class="hidden"><a id="jr-pi-prev" class="hidden" title="Previous page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M75,30 c-80,60 -80,0 0,60 c-30,-60 -30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Prev</text></svg></a><div class="pginfo">Page <i class="jr-pg-pn">0</i> of <i class="jr-pg-lp">0</i></div><a id="jr-pi-next" class="hidden" title="Next page"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M25,30c80,60 80,0 0,60 c30,-60 30,0 0,-60"></path><text x="20" y="28" textLength="60" style="font-size:25px">Next</text></svg></a></div><div id="jr-is-tb"><a id="jr-is-sw" class="btn wsprkl hidden" title="Switch between Figures/Tables strip and Progress bar"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><rect x="10" y="40" width="20" height="20"></rect><rect x="40" y="40" width="20" height="20"></rect><rect x="70" y="40" width="20" height="20"></rect></svg></a></div><nav id="jr-istrip" class="istrip hidden"><a id="jr-is-prev" href="#" class="hidden" title="Previous"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M80,40 60,65 80,90 70,90 50,65 70,40z M50,40 30,65 50,90 40,90 20,65 40,40z"></path><text x="35" y="25" textLength="60" style="font-size:25px">Prev</text></svg></a><a id="jr-is-next" href="#" class="hidden" title="Next"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M20,40 40,65 20,90 30,90 50,65 30,40z M50,40 70,65 50,90 60,90 80,65 60,40z"></path><text x="15" y="25" textLength="60" style="font-size:25px">Next</text></svg></a></nav><nav id="jr-progress"></nav></nav></nav><aside id="jr-links-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">NCBI Bookshelf</div></div><div class="cnt lol f1"><a href="/books/">Home</a><a href="/books/browse/">Browse All Titles</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://www.facebook.com/sharer/sharer.php?u=https://www.ncbi.nlm.nih.gov/books/NBK603289/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24" preserveAspectRatio="none"><g><path d="M 17.996,32L 12,32 L 12,16 l-4,0 l0-5.514 l 4-0.002l-0.006-3.248C 11.993,2.737, 13.213,0, 18.512,0l 4.412,0 l0,5.515 l-2.757,0 c-2.063,0-2.163,0.77-2.163,2.209l-0.008,2.76l 4.959,0 l-0.585,5.514L 18,16L 17.996,32z"></path></g></svg> Share on Facebook</a><a class="btn share" target="_blank" rel="noopener noreferrer" href="https://twitter.com/intent/tweet?url=https://www.ncbi.nlm.nih.gov/books/NBK603289/&text=Evidence%20review%20for%20monitoring%20for%20gastric%20cancer%20in%20people%20with%20vitamin%20B12%20deficiency%20due%20to%20autoimmune%20gast..."><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 33 33" style="vertical-align:middle" width="24" height="24"><g><path d="M 32,6.076c-1.177,0.522-2.443,0.875-3.771,1.034c 1.355-0.813, 2.396-2.099, 2.887-3.632 c-1.269,0.752-2.674,1.299-4.169,1.593c-1.198-1.276-2.904-2.073-4.792-2.073c-3.626,0-6.565,2.939-6.565,6.565 c0,0.515, 0.058,1.016, 0.17,1.496c-5.456-0.274-10.294-2.888-13.532-6.86c-0.565,0.97-0.889,2.097-0.889,3.301 c0,2.278, 1.159,4.287, 2.921,5.465c-1.076-0.034-2.088-0.329-2.974-0.821c-0.001,0.027-0.001,0.055-0.001,0.083 c0,3.181, 2.263,5.834, 5.266,6.438c-0.551,0.15-1.131,0.23-1.73,0.23c-0.423,0-0.834-0.041-1.235-0.118 c 0.836,2.608, 3.26,4.506, 6.133,4.559c-2.247,1.761-5.078,2.81-8.154,2.81c-0.53,0-1.052-0.031-1.566-0.092 c 2.905,1.863, 6.356,2.95, 10.064,2.95c 12.076,0, 18.679-10.004, 18.679-18.68c0-0.285-0.006-0.568-0.019-0.849 C 30.007,8.548, 31.12,7.392, 32,6.076z"></path></g></svg> Share on Twitter</a></div></aside><aside id="jr-cmap-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">In Page Navigation</div></div><div class="cnt lol f1"><a href="/books/n/niceercollect/?report=reader">NICE Evidence Reviews Collection</a><a class="current">Title Information</a></div></aside><aside id="jr-help-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Settings</div></div><div class="cnt f1"><div id="jr-typo-p" class="typo"><div><a class="sf btn wsprkl">A-</a><a class="lf btn wsprkl">A+</a></div><div><a class="bcol-auto btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 100" preserveAspectRatio="none"><text x="10" y="70" style="font-size:60px;font-family: Trebuchet MS, ArialMT, Arial, sans-serif" textLength="180">AUTO</text></svg></a><a class="bcol-1 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M15,25 85,25zM15,40 85,40zM15,55 85,55zM15,70 85,70z"></path></svg></a><a class="bcol-2 btn wsprkl"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 100 100" preserveAspectRatio="none"><path d="M5,25 45,25z M55,25 95,25zM5,40 45,40z M55,40 95,40zM5,55 45,55z M55,55 95,55zM5,70 45,70z M55,70 95,70z"></path></svg></a></div></div><div class="lol"><a class="" href="/books/NBK603289/?report=classic">Switch to classic view</a><a href="/books/n/niceng239er7/pdf/">PDF (793K)</a><a href="/books/n/niceng239er7/toc/?report=printable">Print View</a></div></div></aside><aside id="jr-bkhelp-p" class="hidden flexv"><div class="tb sk-htbar flexh"><div><a class="jr-p-close btn wsprkl">Done</a></div><div class="title-text f1">Help</div></div><div class="cnt f1 lol"><a id="jr-helpobj-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/help.xml" href="">Help</a><a href="mailto:info@ncbi.nlm.nih.gov?subject=PubReader%20feedback%20%2F%20NBK603289%20%2F%20sid%3ACE8B5AF87C7FFCB1_0191SID%20%2F%20phid%3ACE8B8B567D6AEBC100000000011400E2.4">Send us feedback</a><a id="jr-about-sw" data-path="/corehtml/pmc/jatsreader/ptpmc_3.22/" data-href="/corehtml/pmc/jatsreader/ptpmc_3.22/img/bookshelf/about.xml" href="">About PubReader</a></div></aside><aside id="jr-objectbox" class="thidden hidden"><div class="jr-objectbox-close wsprkl">✘</div><div class="jr-objectbox-inner cnt"><div class="jr-objectbox-drawer"></div></div></aside><nav id="jr-pm-left" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Previous Page</text></svg></nav><nav id="jr-pm-right" class="hidden"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 40 800" preserveAspectRatio="none"><text font-stretch="ultra-condensed" x="800" y="-15" text-anchor="end" transform="rotate(90)" font-size="18" letter-spacing=".1em">Next Page</text></svg></nav><nav id="jr-fip" class="hidden"><nav id="jr-fip-term-p"><input type="search" placeholder="search this page" id="jr-fip-term" autocorrect="off" autocomplete="off" /><a id="jr-fip-mg" class="wsprkl btn" title="Find"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 550 600" preserveAspectRatio="none"><path fill="none" stroke="#000" stroke-width="36" stroke-linecap="round" style="fill:#FFF" d="m320,350a153,153 0 1,0-2,2l170,170m-91-117 110,110-26,26-110-110"></path></svg></a><a id="jr-fip-done" class="wsprkl btn" title="Dismiss find">✘</a></nav><nav id="jr-fip-info-p"><a id="jr-fip-prev" class="wsprkl btn" title="Jump to previuos match">◀</a><button id="jr-fip-matches">no matches yet</button><a id="jr-fip-next" class="wsprkl btn" title="Jump to next match">▶</a></nav></nav></div><div id="jr-epub-interstitial" class="hidden"></div><div id="jr-content"><article data-type="main"><div class="main-content lit-style"><div class="fm-sec bkr_bottom_sep"><div class="bkr_thumb"><a href="https://www.nice.org.uk" title="National Institute for Health and Care Excellence (NICE)" class="img_link icnblk_img" ref="pagearea=logo&targetsite=external&targetcat=link&targettype=publisher"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-niceng239er7-lrg.png" alt="Cover of Evidence review for monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis" /></a></div><div class="bkr_bib"><h1 id="_NBK603289_"><span itemprop="name">Evidence review for monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis</span></h1><div class="subtitle">Vitamin B12 deficiency in over 16s: diagnosis and management</div><p><b>Evidence review G</b></p><p><i>NICE Guideline, No. 239</i></p><div class="half_rhythm">London: <a href="https://www.nice.org.uk" ref="pagearea=meta&targetsite=external&targetcat=link&targettype=publisher"><span itemprop="publisher">National Institute for Health and Care Excellence (NICE)</span></a>; <span itemprop="datePublished">2024 Mar</span>.<div class="small">ISBN-13: <span itemprop="isbn">978-1-4731-5735-4</span></div></div><div><a href="/books/about/copyright/">Copyright</a> © NICE 2024.</div></div><div class="bkr_clear"></div></div><div id="niceng239er7.s1"><h2 id="_niceng239er7_s1_">1. Monitoring for gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis</h2><div id="niceng239er7.s1.1"><h3>1.1. Review question</h3><p>What monitoring should be offered to people with pernicious anaemia to identify gastric cancer?</p><div id="niceng239er7.s1.1.1"><h4>1.1.1. Introduction</h4><p>Intrinsic factor is essential for the normal absorption of vitamin B12. Intrinsic factor is produced by the parietal cells of the stomach. Inflammatory conditions of the stomach, predominantly autoimmune gastritis and less commonly H. pylori infection, can lead to the dysfunction and the eventual loss of parietal cells in the stomach, resulting in vitamin B12 deficiency. Previous studies have suggested that several types of cancer affecting the cells of the stomach may be more likely to occur in some people who have vitamin B12 deficiency. This increased risk of stomach cancer development is not due to the vitamin B12 deficiency itself, but the associated stomach inflammation. The two main types of stomach cancer involved are gastric adenocarcinomas and gastric neuroendocrine tumours. The increased risk is therefore only found in those patients who have a gastric cause of vitamin B12 deficiency. This association is plausible given that both the chronic inflammation and the physiological changes such as reduced gastric acid secretion are possible risk factors for stomach cancer development.</p><p>The overall risk of cancers affecting the stomach in people with autoimmune gastritis is uncertain. There is no standardised approach to screening and surveillance of the stomach for cancers. The yield and clinical benefit of such screening, as well as the optimal methodology and frequency of monitoring, have not been previously defined.</p><p>This review seeks to assess the most clinically and cost-effective monitoring strategy to identify gastric cancer in people with vitamin B12 deficiency due to autoimmune gastritis, including the type of procedures and frequency.</p></div><div id="niceng239er7.s1.1.2"><h4>1.1.2. Summary of the protocol</h4><p>For full details see the review protocol in <a href="#niceng239er7.appa">Appendix A</a>.</p><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7tab1"><a href="/books/NBK603289/table/niceng239er7.tab1/?report=objectonly" target="object" title="Table 1" class="img_link icnblk_img" rid-ob="figobniceng239er7tab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.tab1"><a href="/books/NBK603289/table/niceng239er7.tab1/?report=objectonly" target="object" rid-ob="figobniceng239er7tab1">Table 1</a></h4><p class="float-caption no_bottom_margin">PICO characteristics of review question. </p></div></div></div><div id="niceng239er7.s1.1.3"><h4>1.1.3. Methods and process</h4><p>This evidence review was developed using the methods and process described in <a href="https://www.nice.org.uk/process/pmg20/chapter/introduction-and-overview" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Developing NICE guidelines: the manual</a>. Methods specific to this review question are described in the review protocol in <a href="#niceng239er7.appa">appendix A</a> and the <a href="/books/NBK603289/bin/NG239-Methods.pdf">methods</a> document.</p><p>Declarations of interest were recorded according to <a href="https://www.nice.org.uk/about/who-we-are/policies-and-procedures" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE’s conflicts of interest policy</a>.</p></div><div id="niceng239er7.s1.1.4"><h4>1.1.4. Effectiveness evidence</h4><div id="niceng239er7.s1.1.4.1"><h5>1.1.4.1. Included studies</h5><p>A search was conducted for randomised trials comparing the effectiveness of monitoring strategies with each other or with no monitoring for gastric cancer in people with pernicious anaemia. No randomised trials were identified that included people with pernicious anaemia only. One randomised controlled trial<a class="bibr" href="#niceng239er7.s1.1.ref2" rid="niceng239er7.s1.1.ref2"><sup>2</sup></a> comparing gastroscopic follow up at 24 months with gastroscopic follow up at 48 months in people with atrophic gastritis was identified. 59.5% of study participants had pernicious anaemia and were therefore considered an indirect population and evidence was downgraded. The study is summarised in <a href="/books/NBK603289/table/niceng239er7.tab2/?report=objectonly" target="object" rid-ob="figobniceng239er7tab2">Table 2</a> below. Evidence from this study is summarised in the clinical evidence summary below (<a href="/books/NBK603289/table/niceng239er7.tab4/?report=objectonly" target="object" rid-ob="figobniceng239er7tab4">Table 4</a>).</p><p>As no direct evidence from randomised trials was identified, a search was conducted for non-randomised studies. Two cohort studies<a class="bibr" href="#niceng239er7.s1.1.ref1" rid="niceng239er7.s1.1.ref1"><sup>1</sup></a><sup>,</sup>
|
|
<a class="bibr" href="#niceng239er7.s1.1.ref6" rid="niceng239er7.s1.1.ref6"><sup>6</sup></a> comparing gastroscopy with no monitoring were included. The studies are summarised in <a href="/books/NBK603289/table/niceng239er7.tab3/?report=objectonly" target="object" rid-ob="figobniceng239er7tab3">Table 3</a> below. Evidence from these studies is summarised in the clinical evidence summary below (<a href="/books/NBK603289/table/niceng239er7.tab5/?report=objectonly" target="object" rid-ob="figobniceng239er7tab5">Table 5</a> and <a href="/books/NBK603289/table/niceng239er7.tab6/?report=objectonly" target="object" rid-ob="figobniceng239er7tab6">6</a>).</p><p>None of the included studies reported whether participants had undergone previous gastric surgery. Evidence was identified for mortality, incidence of carcinoid tumours and gastric carcinoma. No evidence was identified for quality of life, stage of cancer at diagnosis/surgical resectability or adverse events.</p><p>No evidence was identified for the effectiveness of barium meal, pepsinogen (followed by gastroscopy for those at high risk), gastrin (followed by gastroscopy for those at high risk), combined pepsinogen + gastrin (followed by gastroscopy for those at high risk), 3 staged pepsinogen, followed by gastrin (followed by gastroscopy for those at high risk), or 3 staged gastrin, followed by pepsinogen (followed by gastroscopy for those at high risk).</p><p>See also the study selection flow chart in <a href="#niceng239er7.appc">Appendix C</a>, study evidence tables in <a href="#niceng239er7.appd">Appendix D</a>, forest plots in <a href="#niceng239er7.appe">Appendix E</a> and GRADE tables in <a href="#niceng239er7.appf">Appendix F</a>.</p></div><div id="niceng239er7.s1.1.4.2"><h5>1.1.4.2. Excluded studies</h5><p>See the excluded studies list in <a href="#niceng239er7.appj">Appendix J</a>.</p></div></div><div id="niceng239er7.s1.1.5"><h4>1.1.5. Summary of studies included in the effectiveness evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7tab2"><a href="/books/NBK603289/table/niceng239er7.tab2/?report=objectonly" target="object" title="Table 2" class="img_link icnblk_img" rid-ob="figobniceng239er7tab2"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.tab2"><a href="/books/NBK603289/table/niceng239er7.tab2/?report=objectonly" target="object" rid-ob="figobniceng239er7tab2">Table 2</a></h4><p class="float-caption no_bottom_margin">Summary of randomised controlled trials included in the evidence review. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7tab3"><a href="/books/NBK603289/table/niceng239er7.tab3/?report=objectonly" target="object" title="Table 3" class="img_link icnblk_img" rid-ob="figobniceng239er7tab3"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.tab3"><a href="/books/NBK603289/table/niceng239er7.tab3/?report=objectonly" target="object" rid-ob="figobniceng239er7tab3">Table 3</a></h4><p class="float-caption no_bottom_margin">Summary of non-randomised studies included in the evidence review. </p></div></div><p>See <a href="#niceng239er7.appd">Appendix D</a> for full evidence tables.</p></div><div id="niceng239er7.s1.1.6"><h4>1.1.6. Summary of the effectiveness evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7tab4"><a href="/books/NBK603289/table/niceng239er7.tab4/?report=objectonly" target="object" title="Table 4" class="img_link icnblk_img" rid-ob="figobniceng239er7tab4"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.tab4"><a href="/books/NBK603289/table/niceng239er7.tab4/?report=objectonly" target="object" rid-ob="figobniceng239er7tab4">Table 4</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Gastroscopy at 24 months versus gastroscopy at 48 months (RCT evidence). </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7tab5"><a href="/books/NBK603289/table/niceng239er7.tab5/?report=objectonly" target="object" title="Table 5" class="img_link icnblk_img" rid-ob="figobniceng239er7tab5"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.tab5"><a href="/books/NBK603289/table/niceng239er7.tab5/?report=objectonly" target="object" rid-ob="figobniceng239er7tab5">Table 5</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Gastroscopy (mean every 14 months) versus no monitoring. </p></div></div><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7tab6"><a href="/books/NBK603289/table/niceng239er7.tab6/?report=objectonly" target="object" title="Table 6" class="img_link icnblk_img" rid-ob="figobniceng239er7tab6"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.tab6"><a href="/books/NBK603289/table/niceng239er7.tab6/?report=objectonly" target="object" rid-ob="figobniceng239er7tab6">Table 6</a></h4><p class="float-caption no_bottom_margin">Clinical evidence summary: Gastroscopic screening versus no monitoring. </p></div></div><p>See <a href="#niceng239er7.appf">Appendix F</a> for full GRADE tables.</p></div><div id="niceng239er7.s1.1.7"><h4>1.1.7. Economic evidence</h4><div id="niceng239er7.s1.1.7.1"><h5>1.1.7.1. Included studies</h5><p>One health economic study with relevant comparisons was included in this review.<a class="bibr" href="#niceng239er7.s1.1.ref3" rid="niceng239er7.s1.1.ref3"><sup>3</sup></a> The study compared using monitoring for cancer using gastroscopy in different population groups. This is summarised in the health economic evidence profile below (<a href="/books/NBK603289/table/niceng239er7.tab7/?report=objectonly" target="object" rid-ob="figobniceng239er7tab7">Table 7</a>) and the health.</p><p>The patient population in the included study all had underlying atrophic gastritis, pernicious anaemia was a stratum in the study.</p></div><div id="niceng239er7.s1.1.7.2"><h5>1.1.7.2. Excluded studies</h5><p>No relevant health economic studies were excluded due to assessment of limited applicability or methodological limitations.</p><p>See also the health economic study selection flow chart in <a href="#niceng239er7.appg">Appendix G</a>.</p></div></div><div id="niceng239er7.s1.1.8"><h4>1.1.8. Summary of included economic evidence</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7tab7"><a href="/books/NBK603289/table/niceng239er7.tab7/?report=objectonly" target="object" title="Table 7" class="img_link icnblk_img" rid-ob="figobniceng239er7tab7"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.tab7"><a href="/books/NBK603289/table/niceng239er7.tab7/?report=objectonly" target="object" rid-ob="figobniceng239er7tab7">Table 7</a></h4><p class="float-caption no_bottom_margin">Health economic evidence profile: Gastroscopy surveillance for people with pernicious anaemia. </p></div></div></div><div id="niceng239er7.s1.1.9"><h4>1.1.9. The committee’s discussion and interpretation of the evidence</h4><div id="niceng239er7.s1.1.9.1"><h5>1.1.9.1. The outcomes that matter most</h5><p>The committee considered mortality, quality of life, diagnosis of cancer, stage of cancer at diagnosis or surgical resectability, incidence of gastric neuroendocrine tumours and procedure related adverse events including bleeding, perforation, and aspiration to be the most important outcomes of monitoring for gastric cancer. All outcomes were considered equally important for decision making and therefore were all rated as critical.</p><p>The purpose of the outcome of stage of cancer at diagnosis or surgical resectability was to determine whether the monitoring strategies help to identify cancer earlier, that is, before it progresses to a higher stage, or beyond surgical removal. However, no evidence was identified for this outcome. No evidence was identified for quality of life, or procedure related adverse events.</p></div><div id="niceng239er7.s1.1.9.2"><h5>1.1.9.2. The quality of the evidence</h5><p>Evidence came from one randomised controlled trial comparing different lengths of gastroscopic follow up and two observational cohort studies comparing gastroscopic follow up with no monitoring. The quality of the evidence for all identified outcomes was very low. The main reasons for downgrading of the quality of the evidence were indirectness, risk of bias and imprecision. No evidence was identified for monitoring with barium meal, pepsinogen, gastrin, or any combination/staged protocols using pepsinogen and gastrin.</p><p>One of the main reasons for downgrading the quality of the evidence was population indirectness. The committee decided when setting the review protocol to stratify the evidence for people who have undergone previous gastric surgery, as the associated risk of developing gastric cancer is higher in this group. However, none of the included studies reported this information, therefore all outcomes were downgraded for serious population indirectness. In addition, the study population in the randomised controlled trial was people with body-predominant atrophic gastritis, sixty per cent of whom had pernicious anaemia. As forty per cent of the study population did not have pernicious anaemia, the evidence from this study was downgraded further for population indirectness. The committee considered the evidence to be relevant to this review as people with pernicious anaemia have atrophic gastritis and it is the atrophic gastritis that increases the risk of gastric cancer rather than the pernicious anaemia itself.</p><p>The committee noted the age of the studies, particularly those conducted over thirty years ago. The committee considered that endoscopic techniques have greatly improved since the studies were carried out and more detailed imaging is now available, allowing detection of smaller or more subtle abnormalities. Therefore, the evidence identified may underestimate the effectiveness of gastroscopic monitoring.</p><p>All evidence was at high or very high risk of bias. In the randomised controlled trial, this was due to the lack of information reported on the randomisation process, deviations from the intended interventions and missing outcome data. In the observational studies, this was due to the lack of adjustment for confounders, classification of interventions and missing data.</p><p>The included studies all had small samples sizes, around one hundred participants or less. This led to imprecision around several of the point estimates. The committee were aware that around one in three hundred people with autoimmune gastritis per year develop gastric cancer. Therefore, the studies were likely to be underpowered to detect any meaningful differences between the monitoring strategies.</p><p>Considering all the limitations outlined above, the committee considered there to be insufficient evidence upon which to base recommendations. The committee agreed that this is an area in which further research is needed and therefore decided to make a recommendation for research.</p></div><div id="niceng239er7.s1.1.9.3"><h5>1.1.9.3. Benefits and harms</h5><p>All the evidence identified was for gastroscopy, with no evidence identified for any other monitoring technique listed in the review protocol. The committee noted that gastroscopy is the only technique that can detect the presence of gastric cancer in people with symptoms. The other methods are more appropriate in the context of assessing risk of developing cancer in people who are asymptomatic.</p><p>Very low-quality evidence suggested a benefit of regular gastroscopy over no monitoring for reducing mortality, although there was very serious imprecision, with wide confidence intervals compatible with no difference and a harm of gastroscopy. Very low-quality evidence also showed a benefit of gastroscopic screening over no monitoring for increasing the identification of carcinoid tumours. No clinically important difference was found between twenty-four and forty-eight month follow up with gastroscopy in the identification of carcinoid tumours. No clinically important difference was found between regular gastroscopy or gastroscopic screening compared with no monitoring for gastric carcinoma. The committee considered there to be insufficient evidence upon which to base recommendations.</p><p>The committee considered what is being done in current clinical practice. Gastroscopy on diagnosis of autoimmune gastritis is not carried out routinely and referral to secondary care depends on local interest and locally available services, GP knowledge and awareness, and tradition. The committee also considered the potential harms of gastroscopic screening or monitoring. No evidence was identified for quality of life or procedure related adverse events; however, the committee discussed the physically uncomfortable nature of the procedure from the patients’ perspective. Therefore, the committee agreed that without sufficient evidence to recommend gastroscopic surveillance for gastric cancer in all people with autoimmune gastritis, gastroscopy should only be offered if there is a clinical reason for doing so.</p><p>If there are symptoms of gastric cancer present, such as new dysphagia, or dyspepsia, nausea and vomiting and weight loss in over 55’s, people are referred urgently to gastroenterology through the two-week cancer referral pathway. Biopsies are taken at gastroscopy and only those with high operative link for gastritis assessment (OLGA) and operative link for gastric intestinal metaplasia assessment (OLGIM) scores would have subsequent or regular gastroscopic monitoring. Identification of small tumours (<10mm) for example, require surveillance rather than treatment. The committee recommended that healthcare professionals consider referral for gastroscopic endoscopy if the person has autoimmune gastritis with new onset upper gastrointestinal symptoms.</p><p>The committee highlighted the need for greater awareness on the upper gastrointestinal symptoms, as well as the increased risk of gastric adenocarcinoma and gastric neuroendocrine tumours in people with autoimmune gastritis. Therefore, this information was included in the wording of the recommendations in the hope that this will raise awareness, particularly among GPs. The committee were also aware of the <a href="https://www.nice.org.uk/guidance/ng12" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">NICE guideline on Suspected cancer</a> and cross referred to the recommendations on lower and upper gastrointestinal tract cancers.</p></div><div id="niceng239er7.s1.1.9.4"><h5>1.1.9.4. Cost effectiveness and resource use</h5><div id="niceng239er7.s1.1.9.4.1"><h5>Economic evidence</h5><p>One economic evaluation was identified for this review. The economic evaluation investigated the cost to detect cancer for people with autoimmune gastritis compared to people with additional risk factors with autoimmune gastritis using gastroscopy surveillance. The patient population in the included study all had underlying atrophic gastritis and autoimmune gastritis was a stratum in the study. The committee considered only the results for people with autoimmune gastritis.</p><p>In the economic evaluation, the cost to detect a cancer for an autoimmune gastritis patient without extensive atrophic gastritis was £14,486 whilst the cost to detect a cancer in an autoimmune gastritis patient population with extensive atrophic gastritis was £2,692.</p><p>The only reported cost was the cost of the gastroscopy (endoscopy) which was valued at £155. There were no costs of cancer treatment included. Routine gastroscopy was not recommended due to the limitations of the study which didn’t consider quality-adjusted life-years or the cost of cancer treatment. Also, the reported gastroscopy cost was deemed to be significantly lower than other published costs; there is a cost of £754 reported in the ‘National schedule of NHS costs 2020-2021’ which would raise the cost to detect gastric cancer to approximately £70,000 for people without extensive atrophic gastritis. This would then potentially have a significant resource impact on the NHS. Furthermore, there was a relatively small sample of people with autoimmune gastritis (102 people) which added to the uncertainty of the results. This was also a non-UK based study which raised applicability concerns.</p><p>No cost-effectiveness evidence was identified for other interventions for monitoring of gastric cancer in people with autoimmune gastritis. There was no evidence for the use of barium meal, pepsinogen, gastrin, or any combination/staged protocols using pepsinogen and gastrin for monitoring.</p></div><div id="niceng239er7.s1.1.9.4.2"><h5>Potential for modelling</h5><p>The committee considered whether it would be feasible to model the cost-effectiveness of gastroscopy for surveillance of gastric cancer for people with autoimmune gastritis. The committee thought that earlier treatment could lead to better outcomes and care savings but there is not the evidence to quantify these outcomes.</p><p>The committee noted that gastroscopy was not always preferred by people due to the uncomfortable nature of the intervention which may impact their utility whilst undergoing the screening. From the clinical review, there was no evidence relating to quality of life.</p><p>The committee were concerned about the lack of available clinical data to inform an economic model specifically for people with autoimmune gastritis and the outcomes for people with autoimmune gastritis that are diagnosed with gastric cancer. The committee were unaware of data relating to the incidence of gastric cancer in people with autoimmune gastritis and the type of cancer as well as stage of cancer when detected. The committee considered whether evidence from other clinical conditions could inform modelling, but they were concerned about the clinical validity of extrapolating evidence from other clinical conditions.</p></div><div id="niceng239er7.s1.1.9.4.3"><h5>Conclusions about cost effectiveness</h5><p>There is a substantial cost of offering gastroscopic surveillance of £754 every two-four years. Earlier identification may improve treatment outcomes and patient QALYs however, there is too much uncertainty and lack of evidence to indicate whether the cost-effectiveness of providing routine gastroscopy is less than £20,000 per QALY gained.</p><p>There was no evidence at all for other forms of surveillance.</p></div><div id="niceng239er7.s1.1.9.4.4"><h5>Recommendations</h5><p>Due to insufficient clinical and cost effectiveness evidence, recommendations for gastroscopy to be offered routinely for surveillance could not be made. There was no evidence at all for other forms of surveillance. The committee members decided to recommend investigating what monitoring should be offered to people with autoimmune gastritis to identify gastric cancer as a research question, and this topic was not subsequently modelled.</p><p>The committee also recommended that clinicians look out for symptoms that might suggest cancer and cross-referred to relevant NICE guidance on cancer diagnosis.</p></div><div id="niceng239er7.s1.1.9.4.5"><h5>Resource impact</h5><p>The committee members thought that some people with autoimmune gastritis that have gastrointestinal symptoms may already be receiving gastroscopic surveillance. Although there was not enough evidence to recommend routine surveillance, the committee did not expect surveillance to stop and so it is not thought there will be any additional resource impact.</p></div></div></div><div id="niceng239er7.s1.1.10"><h4>1.1.10. Recommendations supported by this evidence review</h4><p>This evidence review supports recommendations 1.7.1 and 1.7.2, and the research recommendation on what monitoring should be offered to people with autoimmune gastritis (also known as pernicious anaemia) to identify gastric cancer.</p></div><div id="niceng239er7.s1.1.rl.r1"><h4>1.1.11. References</h4><dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>1.</dt><dd><div class="bk_ref" id="niceng239er7.s1.1.ref1">Armbrecht
|
|
U, Stockbrugger
|
|
RW, Rode
|
|
J, Menon
|
|
GG, Cotton
|
|
PB. Development of gastric dysplasia in pernicious anaemia: a clinical and endoscopic follow up study of 80 patients. Gut. 1990; 31(10):1105–1109
|
|
[<a href="/pmc/articles/PMC1378732/" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1378732</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2083855" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2083855</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>2.</dt><dd><div class="bk_ref" id="niceng239er7.s1.1.ref2">Lahner
|
|
E, Caruana
|
|
P, D’Ambra
|
|
G, Ferraro
|
|
G, Di Giulio
|
|
E, Delle Fave
|
|
G
|
|
et al. First endoscopic-histologic follow-up in patients with body-predominant atrophic gastritis: when should it be done?
|
|
Gastrointestinal Endoscopy. 2001; 53(4):443–448
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/11275884" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 11275884</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>3.</dt><dd><div class="bk_ref" id="niceng239er7.s1.1.ref3">Lahner
|
|
E, Hassan
|
|
C, Esposito
|
|
G, Carabotti
|
|
M, Zullo
|
|
A, Dinis-Ribeiro
|
|
M
|
|
et al. Cost of detecting gastric neoplasia by surveillance endoscopy in atrophic gastritis in Italy: A low risk country. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. 2017; 49(3):291–296
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28034664" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28034664</span></a>]</div></dd></dl><dl class="bkr_refwrap"><dt>4.</dt><dd><div class="bk_ref" id="niceng239er7.s1.1.ref4">National Institute for Health and Care Excellence. Developing NICE guidelines: the manual [updated January
|
|
2022]. London. National Institute for Health and Care Excellence, 2014. Available from: <a href="http://www.nice.org.uk/article/PMG20/chapter/1%20Introduction%20and%20overview" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">http://www<wbr style="display:inline-block"></wbr>​.nice.org.uk<wbr style="display:inline-block"></wbr>​/article/PMG20/chapter<wbr style="display:inline-block"></wbr>​/1%20Introduction%20and%20overview</a></div></dd></dl><dl class="bkr_refwrap"><dt>5.</dt><dd><div class="bk_ref" id="niceng239er7.s1.1.ref5">Organisation for Economic Co-operation and Development (OECD). Purchasing power parities (PPP). 2021. Available from: <a href="https://data.oecd.org/conversion/purchasing-power-parities-ppp.htm" ref="pagearea=cite-ref&targetsite=external&targetcat=link&targettype=uri">https://data<wbr style="display:inline-block"></wbr>​.oecd.org<wbr style="display:inline-block"></wbr>​/conversion/purchasing-power-parities-ppp.htm</a> Last accessed: 01/06/2022.</div></dd></dl><dl class="bkr_refwrap"><dt>6.</dt><dd><div class="bk_ref" id="niceng239er7.s1.1.ref6">Sjoblom
|
|
SM, Sipponen
|
|
P, Miettinen
|
|
M, Karonen
|
|
SL, Jrvinen
|
|
HJ. Gastroscopic screening for gastric carcinoids and carcinoma in pernicious anemia. Endoscopy. 1988; 20(2):52–56
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/3383791" ref="pagearea=cite-ref&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3383791</span></a>]</div></dd></dl></dl></div></div></div><div id="appendixesappgroup1"><h2 id="_appendixesappgroup1_">Appendices</h2><div id="niceng239er7.appa"><h3>Appendix A. Review protocols</h3><p id="niceng239er7.appa.et1"><a href="/books/NBK603289/bin/niceng239er7-appa-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Review protocol for monitoring for gastric cancer in people with pernicious anaemia</a><span class="small"> (PDF, 168K)</span></p><p id="niceng239er7.appa.et2"><a href="/books/NBK603289/bin/niceng239er7-appa-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Health economic review protocol</a><span class="small"> (PDF, 135K)</span></p></div><div id="niceng239er7.appb"><h3>Appendix B. Literature search strategies</h3><p>The literature searches for this review are detailed below and complied with the methodology outlined in Developing NICE guidelines: the manual.<a class="bibr" href="#niceng239er7.s1.1.ref4" rid="niceng239er7.s1.1.ref4"><sup>4</sup></a></p><p>For more information, please see the Methodology review published as part of the accompanying documents for this guideline.</p><div id="niceng239er7.appb.s1"><h4>B.1. What monitoring should be offered to people with pernicious anaemia to identify gastric cancer?</h4><p id="niceng239er7.appb.et1"><a href="/books/NBK603289/bin/niceng239er7-appb-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.1.1. Clinical search literature search strategy</a><span class="small"> (PDF, 126K)</span></p><p id="niceng239er7.appb.et2"><a href="/books/NBK603289/bin/niceng239er7-appb-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">B.1.2. Health Economics literature search strategy</a><span class="small"> (PDF, 135K)</span></p></div></div><div id="niceng239er7.appc"><h3>Appendix C. Effectiveness evidence study selection</h3><p id="niceng239er7.appc.et1"><a href="/books/NBK603289/bin/niceng239er7-appc-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Figure 1. Flow chart of clinical study selection for the review of monitoring for gastric cancer in people with pernicious anaemia</a><span class="small"> (PDF, 64K)</span></p></div><div id="niceng239er7.appd"><h3>Appendix D. Effectiveness evidence</h3><p id="niceng239er7.appd.et1"><a href="/books/NBK603289/bin/niceng239er7-appd-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (198K)</span></p></div><div id="niceng239er7.appe"><h3>Appendix E. Forest plots</h3><p id="niceng239er7.appe.et1"><a href="/books/NBK603289/bin/niceng239er7-appe-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.1. Gastroscopy at 24 months versus gastroscopy at 48 months (RCT evidence)</a><span class="small"> (PDF, 92K)</span></p><p id="niceng239er7.appe.et2"><a href="/books/NBK603289/bin/niceng239er7-appe-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.2. Gastroscopy (mean every 14 months) versus no monitoring</a><span class="small"> (PDF, 94K)</span></p><p id="niceng239er7.appe.et3"><a href="/books/NBK603289/bin/niceng239er7-appe-et3.pdf" class="bk_dwnld_icn bk_dwnld_pdf">E.3. Gastroscopic screening versus no monitoring</a><span class="small"> (PDF, 95K)</span></p></div><div id="niceng239er7.appf"><h3>Appendix F. GRADE tables</h3><p id="niceng239er7.appf.et1"><a href="/books/NBK603289/bin/niceng239er7-appf-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Table 10. Clinical evidence profile: Gastroscopy at 24 months versus gastroscopy at 48 months</a><span class="small"> (PDF, 189K)</span></p></div><div id="niceng239er7.appg"><h3>Appendix G. Economic evidence study selection</h3><p id="niceng239er7.appg.et1"><a href="/books/NBK603289/bin/niceng239er7-appg-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (164K)</span></p></div><div id="niceng239er7.apph"><h3>Appendix H. Economic evidence tables</h3><p id="niceng239er7.apph.et1"><a href="/books/NBK603289/bin/niceng239er7-apph-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (129K)</span></p></div><div id="niceng239er7.appi"><h3>Appendix I. Health economic model</h3><p>None.</p></div><div id="niceng239er7.appj"><h3>Appendix J. Excluded studies</h3><div id="niceng239er7.appj.s1"><h4>Clinical studies</h4><div class="iconblock whole_rhythm clearfix ten_col table-wrap" id="figniceng239er7appjtab1"><a href="/books/NBK603289/table/niceng239er7.appj.tab1/?report=objectonly" target="object" title="Table 13" class="img_link icnblk_img" rid-ob="figobniceng239er7appjtab1"><img class="small-thumb" src="/corehtml/pmc/css/bookshelf/2.26/img/table-icon.gif" alt="Table Icon" /></a><div class="icnblk_cntnt"><h4 id="niceng239er7.appj.tab1"><a href="/books/NBK603289/table/niceng239er7.appj.tab1/?report=objectonly" target="object" rid-ob="figobniceng239er7appjtab1">Table 13</a></h4><p class="float-caption no_bottom_margin">Studies excluded from the clinical review. </p></div></div></div><div id="niceng239er7.appj.s2"><h4>Health Economic studies</h4><p>None.</p></div></div><div id="niceng239er7.appk"><h3>Appendix K. Research recommendations – full details</h3><div id="niceng239er7.appk.s1"><h4>K.1. Research recommendation</h4><p>What monitoring should be offered to people with autoimmune gastritis (also known as pernicious anaemia) to identify gastric cancer?</p><div id="niceng239er7.appk.s1.1"><h5>K.1.1. Why this is important</h5><p>People with autoimmune gastritis have and an increased risk of gastric adenocarcinoma and gastric neuroendocrine tumours compared with the general population. There is insufficient evidence to determine the type and extent of monitoring for gastric cancer that leads to the best outcomes for people with autoimmune gastritis.</p></div><div id="niceng239er7.appk.s1.2"><h5>K.1.2. Rationale for research recommendation</h5><p id="niceng239er7.appk.et1"><a href="/books/NBK603289/bin/niceng239er7-appk-et1.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (94K)</span></p></div><div id="niceng239er7.appk.s1.3"><h5>K.1.3. Modified PICO table</h5><p id="niceng239er7.appk.et2"><a href="/books/NBK603289/bin/niceng239er7-appk-et2.pdf" class="bk_dwnld_icn bk_dwnld_pdf">Download PDF</a><span class="small"> (115K)</span></p></div></div></div></div></div><div class="fm-sec"><div><p>Final</p></div><div><p>Evidence reviews underpinning recommendations 1.7.1 and 1.7.2 and the recommendation for research in the NICE guideline</p><p>Developed by NICE</p></div><div><p><b>Disclaimer</b>: The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.</p><p>Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.</p><p>NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <a href="https://www.gov.wales/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Welsh Government</a>, <a href="http://www.scotland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Scottish Government</a>, and <a href="http://www.northernireland.gov.uk/" ref="pagearea=body&targetsite=external&targetcat=link&targettype=uri">Northern Ireland Executive</a>. All NICE guidance is subject to regular review and may be updated or withdrawn.</p></div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © NICE 2024.</div><div class="small"><span class="label">Bookshelf ID: NBK603289</span><span class="label">PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/38691633" title="PubMed record of this title" ref="pagearea=meta&targetsite=entrez&targetcat=link&targettype=pubmed">38691633</a></span></div></div><div class="small-screen-prev"></div><div class="small-screen-next"></div></article><article data-type="table-wrap" id="figobniceng239er7tab1"><div id="niceng239er7.tab1" class="table"><h3><span class="label">Table 1</span><span class="title">PICO characteristics of review question</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.tab1_lrgtbl__"><table><tbody><tr><th id="hd_b_niceng239er7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><td headers="hd_b_niceng239er7.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Inclusion: adults with diagnosed pernicious anaemia (diagnosis as defined by the studies)</p>
|
|
<p>Exclusion: other types/causes of vitamin B12 deficiency</p>
|
|
<p>Strata:</p>
|
|
<p>Other risk factors for gastric cancer (patients with any previous gastric surgery, including bariatric surgery)</p>
|
|
</td></tr><tr><th id="hd_b_niceng239er7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Interventions</th><td headers="hd_b_niceng239er7.tab1_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Monitoring for gastric cancer:
|
|
<ul class="circle"><li class="half_rhythm"><div>Gastroscopy</div></li><li class="half_rhythm"><div>Barium meal</div></li><li class="half_rhythm"><div>Pepsinogen (followed by gastroscopy for those at high risk)</div></li><li class="half_rhythm"><div>Gastrin (followed by gastroscopy for those at high risk)</div></li><li class="half_rhythm"><div>Combined pepsinogen + gastrin (followed by gastroscopy for those at high risk)</div></li><li class="half_rhythm"><div>3 staged pepsinogen, followed by gastrin (followed by gastroscopy for those at high risk)</div></li><li class="half_rhythm"><div>3 staged gastrin, followed by pepsinogen (followed by gastroscopy for those at high risk)</div></li></ul></div></li></ul>
|
|
<p>Stratify by:</p>
|
|
<p>Frequency</p></td></tr><tr><th id="hd_b_niceng239er7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comparisons</th><td headers="hd_b_niceng239er7.tab1_1_1_3_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>All monitoring strategies compared with each other (what is included and frequency of monitoring)</div></li><li class="half_rhythm"><div>No monitoring</div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng239er7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><td headers="hd_b_niceng239er7.tab1_1_1_4_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">All outcomes are considered equally important for decision making and therefore have all been rated as critical:
|
|
<ul><li class="half_rhythm"><div>Mortality</div></li><li class="half_rhythm"><div>Quality of life</div></li><li class="half_rhythm"><div>Diagnosis of cancer</div></li><li class="half_rhythm"><div>Stage of cancer at diagnosis/surgical resectability</div></li><li class="half_rhythm"><div>Incidence of gastric neuroendocrine tumours (AKA carcinoid tumours/NETS/NENS)</div></li><li class="half_rhythm"><div>Adverse events (procedure related):
|
|
<ul class="circle"><li class="half_rhythm"><div>bleeding</div></li><li class="half_rhythm"><div>perforation</div></li><li class="half_rhythm"><div>aspiration</div></li></ul></div></li></ul>
|
|
</td></tr><tr><th id="hd_b_niceng239er7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study design</th><td headers="hd_b_niceng239er7.tab1_1_1_5_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Randomised controlled trials</div></li><li class="half_rhythm"><div>Systematic reviews of RCTs</div></li><li class="half_rhythm"><div>Non-randomised studies if insufficient RCT evidence is identified (priority will be given to inclusion of non-randomised comparative studies that have controlled/adjusted for confounding factors. If insufficient evidence is identified from studies that have controlled/adjusted for confounding factors, non-randomised comparative studies that have not controlled/adjusted for confounding factors will be considered)</div><div>Key confounders: previous gastric surgery</div></li></ul>
|
|
<p>Published NMAs and IPDs will be considered for inclusion.</p></td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng239er7tab2"><div id="niceng239er7.tab2" class="table"><h3><span class="label">Table 2</span><span class="title">Summary of randomised controlled trials included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.tab2/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.tab2_lrgtbl__"><table><thead><tr><th id="hd_h_niceng239er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng239er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention and comparison</th><th id="hd_h_niceng239er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><th id="hd_h_niceng239er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><th id="hd_h_niceng239er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng239er7.tab2_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lahner 2001<a class="bibr" href="#niceng239er7.s1.1.ref2" rid="niceng239er7.s1.1.ref2"><sup>2</sup></a></td><td headers="hd_h_niceng239er7.tab2_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Gastroscopy at 24 months</b>
|
|
<i>N=30</i></p>
|
|
<p>Invited to undergo follow-up at a median of 24 months (range 20-26 months) after diagnosis of body-predominant atrophic gastritis</p>
|
|
<p>Versus</p>
|
|
<p><b>Gastroscopy at 48 months</b>
|
|
<i>N=31</i></p>
|
|
<p>Follow-up scheduled at a median of 48 months (range 38-60 months)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab2_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Outpatients with body-predominant atrophic gastritis recruited in a screening program for early detection of BAG in patients with unexplained anaemia or long-standing dyspepsia. 59.5% had pernicious anaemia.</p>
|
|
<p>Population strata (previous gastric surgery): not reported</p>
|
|
<p>Age: group A median (range) 55.5 (22-68) years, group B 59.5 (28-73) years</p>
|
|
<p>Sex: 15 males, 27 females</p>
|
|
</td><td headers="hd_h_niceng239er7.tab2_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>At 2 vs. 4 years:</p>
|
|
<p>Carcinoid tumours</p>
|
|
</td><td headers="hd_h_niceng239er7.tab2_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Criteria for diagnosis of body–predominant atrophic gastritis: fasting gastrin above upper normal values, hypochlorhydria/achlorhydria to pentagastrin stimulation, and histologic confirmation of gastric body mucosal atrophy.</p>
|
|
<p>Criteria for diagnosis of pernicious anaemia: macrocytic anaemia (haemoglobin levels less than 14 g/dL for men and less than 12 g/dL for women; mean corpuscular volume greater than 100 fL), vitamin B12 levels less than 220 pg/mL (normal range 220 to 1130 pg/mL), recovery from anaemia after treatment with intramuscular vitamin B12, hypochlorhydria/achlorhydria to pentagastrin stimulation, and histologic confirmation of gastric body mucosa atrophy.</p>
|
|
<p>Conducted in Italy</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng239er7tab3"><div id="niceng239er7.tab3" class="table"><h3><span class="label">Table 3</span><span class="title">Summary of non-randomised studies included in the evidence review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.tab3/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.tab3_lrgtbl__"><table><thead><tr><th id="hd_h_niceng239er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng239er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Intervention and comparison</th><th id="hd_h_niceng239er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Population</th><th id="hd_h_niceng239er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Outcomes</th><th id="hd_h_niceng239er7.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Comments</th></tr></thead><tbody><tr><td headers="hd_h_niceng239er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Armbrecht 1990<a class="bibr" href="#niceng239er7.s1.1.ref1" rid="niceng239er7.s1.1.ref1"><sup>1</sup></a></td><td headers="hd_h_niceng239er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Gastroscopy</b>
|
|
<i>N=12</i></p>
|
|
<p>Histories of clinical symptoms taken and upper gastrointestinal endoscopies performed at a mean interval of 14 months</p>
|
|
<p>Versus</p>
|
|
<p><b>No monitoring</b>
|
|
<i>N=61</i></p>
|
|
<p>No further information</p>
|
|
</td><td headers="hd_h_niceng239er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patients recruited to a previous study on gastroscopic screening in pernicious anaemia.</p>
|
|
<p>Population strata (previous gastric surgery): not reported</p>
|
|
<p>Age: 20-79 years (median 63 years at first investigation)</p>
|
|
<p>35 women, 44 men</p>
|
|
</td><td headers="hd_h_niceng239er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>At mean 6.4 years:</p>
|
|
<p>Mortality</p>
|
|
<p>Gastric carcinoma</p>
|
|
</td><td headers="hd_h_niceng239er7.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Unclear how 12 patients were selected for regular follow up</p>
|
|
<p>Conducted in UK</p>
|
|
</td></tr><tr><td headers="hd_h_niceng239er7.tab3_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Sjoblom 1988<a class="bibr" href="#niceng239er7.s1.1.ref6" rid="niceng239er7.s1.1.ref6"><sup>6</sup></a></td><td headers="hd_h_niceng239er7.tab3_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p><b>Gastroscopy</b>
|
|
<i>N=71</i></p>
|
|
<p>Gastroscopic screening</p>
|
|
<p>Versus</p>
|
|
<p><b>No monitoring</b>
|
|
<i>N=34</i></p>
|
|
<p>Patients who did not attend screening.</p>
|
|
</td><td headers="hd_h_niceng239er7.tab3_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Patients with pernicious anaemia, examined as inpatients (1972-1985) or outpatients (1980-1985); aged ≤75 years</p>
|
|
<p>Population strata (previous gastric surgery): no information reported</p>
|
|
<p>Age: ≤75 years, no further information reported</p>
|
|
<p>Sex: no information reported</p>
|
|
</td><td headers="hd_h_niceng239er7.tab3_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>At mean 7 years:</p>
|
|
<p>Gastric carcinoid tumours</p>
|
|
<p>Gastric carcinoma</p>
|
|
</td><td headers="hd_h_niceng239er7.tab3_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<p>Criteria for diagnosis of PA:</p>
|
|
<p>1. Macrocytic anaemia and/or megaloblastic bone marrow and/or subnormal serum levels of vitamin B12.</p>
|
|
<p>2. Schilling test showing intrinsic factor deficiency, pentagastrin-fast achlorhydria or histologically verified fundic atrophic gastritis.</p>
|
|
<p>Conducted in Finland</p>
|
|
</td></tr></tbody></table></div></div></article><article data-type="table-wrap" id="figobniceng239er7tab4"><div id="niceng239er7.tab4" class="table"><h3><span class="label">Table 4</span><span class="title">Clinical evidence summary: Gastroscopy at 24 months versus gastroscopy at 48 months (RCT evidence)</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.tab4/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.tab4_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng239er7.tab4_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab4_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng239er7.tab4_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab4_1_1_1_2" style="text-align:center;vertical-align:middle;">
|
|
<p>№ of participants (studies)</p>
|
|
<p>Follow-up</p>
|
|
</th><th id="hd_h_niceng239er7.tab4_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab4_1_1_1_3" style="text-align:center;vertical-align:middle;">
|
|
<p>Certainty of the evidence</p>
|
|
<p>(GRADE)</p>
|
|
</th><th id="hd_h_niceng239er7.tab4_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab4_1_1_1_4" style="text-align:center;vertical-align:middle;">
|
|
<p>Relative effect</p>
|
|
<p>(95% CI)</p>
|
|
</th><th id="hd_h_niceng239er7.tab4_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng239er7.tab4_1_1_1_5" id="hd_h_niceng239er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with gastroscopy at 48 months</th><th headers="hd_h_niceng239er7.tab4_1_1_1_5" id="hd_h_niceng239er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with Gastroscopy at 24 months</th></tr></thead><tbody><tr><td headers="hd_h_niceng239er7.tab4_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Carcinoid tumours</td><td headers="hd_h_niceng239er7.tab4_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>42</p>
|
|
<p>(1 RCT)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab4_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng239er7.tab4_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>OR 0.12</b>
|
|
</p>
|
|
<p>(0.00 to 6.20)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab4_1_1_1_5 hd_h_niceng239er7.tab4_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">50 per 1,000</td><td headers="hd_h_niceng239er7.tab4_1_1_1_5 hd_h_niceng239er7.tab4_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>50 fewer per 1,000</b>
|
|
</p>
|
|
<p>(180 fewer to 80 more)<sup>d</sup></p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng239er7.tab4_1"><p class="no_margin">High risk of bias due to lack of information reported on the randomisation process, deviations from the intended interventions and missing outcome data</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng239er7.tab4_2"><p class="no_margin">Very serious population indirectness due to lack of information reported on previous gastric surgery and not all participants having pernicious anaemia</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng239er7.tab4_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID and by 2 increments if the confidence interval crossed two MIDs (0.8 and 1.25 for dichotomous outcomes; 0.5 * median of baseline SD of the intervention and control group for continuous outcomes).</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng239er7.tab4_4"><p class="no_margin">Absolute effects calculated using risk difference</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng239er7tab5"><div id="niceng239er7.tab5" class="table"><h3><span class="label">Table 5</span><span class="title">Clinical evidence summary: Gastroscopy (mean every 14 months) versus no monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.tab5/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.tab5_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng239er7.tab5_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab5_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng239er7.tab5_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab5_1_1_1_2" style="text-align:center;vertical-align:middle;">
|
|
<p>№ of participants (studies)</p>
|
|
<p>Follow-up</p>
|
|
</th><th id="hd_h_niceng239er7.tab5_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab5_1_1_1_3" style="text-align:center;vertical-align:middle;">
|
|
<p>Certainty of the evidence</p>
|
|
<p>(GRADE)</p>
|
|
</th><th id="hd_h_niceng239er7.tab5_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab5_1_1_1_4" style="text-align:center;vertical-align:middle;">
|
|
<p>Relative effect</p>
|
|
<p>(95% CI)</p>
|
|
</th><th id="hd_h_niceng239er7.tab5_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng239er7.tab5_1_1_1_5" id="hd_h_niceng239er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with no monitoring</th><th headers="hd_h_niceng239er7.tab5_1_1_1_5" id="hd_h_niceng239er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with Gastroscopy (mean every 14 months)</th></tr></thead><tbody><tr><td headers="hd_h_niceng239er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Mortality</td><td headers="hd_h_niceng239er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>73</p>
|
|
<p>(1 observational study)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng239er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RR 0.73</b>
|
|
</p>
|
|
<p>(0.10 to 5.38)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab5_1_1_1_5 hd_h_niceng239er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">115 per 1,000</td><td headers="hd_h_niceng239er7.tab5_1_1_1_5 hd_h_niceng239er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>31 fewer per 1,000</b>
|
|
</p>
|
|
<p>(103 fewer to 503 more)</p>
|
|
</td></tr><tr><td headers="hd_h_niceng239er7.tab5_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Gastric carcinoma</td><td headers="hd_h_niceng239er7.tab5_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>73</p>
|
|
<p>(1 observational study)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab5_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>Very low<sup>b</sup><sup>,</sup><sup>d</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng239er7.tab5_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RD 0.00</b>
|
|
</p>
|
|
<p>(−0.11 to 0.11)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab5_1_1_1_5 hd_h_niceng239er7.tab5_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0 per 1,000</td><td headers="hd_h_niceng239er7.tab5_1_1_1_5 hd_h_niceng239er7.tab5_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(0 fewer to 0 fewer)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng239er7.tab5_1"><p class="no_margin">Very high risk of bias due to confounding and classification of interventions</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng239er7.tab5_2"><p class="no_margin">Serious population indirectness due to lack of information reported on previous gastric surgery</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng239er7.tab5_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID and by 2 increments if the confidence interval crossed two MIDs (0.8 and 1.25 for dichotomous outcomes; 0.5 * median of baseline SD of the intervention and control group for continuous outcomes)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng239er7.tab5_4"><p class="no_margin">Very high risk of bias due to confounding, classification of interventions and measurement of outcomes</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng239er7.tab5_5"><p class="no_margin">Serious imprecision (risk difference and sample size >70<350)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng239er7tab6"><div id="niceng239er7.tab6" class="table"><h3><span class="label">Table 6</span><span class="title">Clinical evidence summary: Gastroscopic screening versus no monitoring</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.tab6/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.tab6_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng239er7.tab6_1_1_1_1" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab6_1_1_1_1" style="text-align:center;vertical-align:middle;">Outcomes</th><th id="hd_h_niceng239er7.tab6_1_1_1_2" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab6_1_1_1_2" style="text-align:center;vertical-align:middle;">
|
|
<p>№ of participants (studies)</p>
|
|
<p>Follow-up</p>
|
|
</th><th id="hd_h_niceng239er7.tab6_1_1_1_3" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab6_1_1_1_3" style="text-align:center;vertical-align:middle;">
|
|
<p>Certainty of the evidence</p>
|
|
<p>(GRADE)</p>
|
|
</th><th id="hd_h_niceng239er7.tab6_1_1_1_4" rowspan="2" colspan="1" headers="hd_h_niceng239er7.tab6_1_1_1_4" style="text-align:center;vertical-align:middle;">
|
|
<p>Relative effect</p>
|
|
<p>(95% CI)</p>
|
|
</th><th id="hd_h_niceng239er7.tab6_1_1_1_5" colspan="2" rowspan="1" style="text-align:center;vertical-align:middle;">Anticipated absolute effects</th></tr><tr><th headers="hd_h_niceng239er7.tab6_1_1_1_5" id="hd_h_niceng239er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk with no monitoring</th><th headers="hd_h_niceng239er7.tab6_1_1_1_5" id="hd_h_niceng239er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Risk difference with Gastroscopic screening</th></tr></thead><tbody><tr><td headers="hd_h_niceng239er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Carcinoid tumours</td><td headers="hd_h_niceng239er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>105</p>
|
|
<p>(1 observational study)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>c</sup></p>
|
|
</td><td headers="hd_h_niceng239er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>OR 4.66</b>
|
|
</p>
|
|
<p>(0.69 to 31.45)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab6_1_1_1_5 hd_h_niceng239er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0 per 1,000</td><td headers="hd_h_niceng239er7.tab6_1_1_1_5 hd_h_niceng239er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>70 more per 1,000</b>
|
|
</p>
|
|
<p>(0 fewer to 140 more)<sup>d</sup></p>
|
|
</td></tr><tr><td headers="hd_h_niceng239er7.tab6_1_1_1_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">Gastric carcinoma</td><td headers="hd_h_niceng239er7.tab6_1_1_1_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>105</p>
|
|
<p>(1 observational study)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab6_1_1_1_3" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>⊕◯◯◯</p>
|
|
<p>Very low<sup>a</sup><sup>,</sup><sup>b</sup><sup>,</sup><sup>e</sup></p>
|
|
</td><td headers="hd_h_niceng239er7.tab6_1_1_1_4" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>RD 0.00</b>
|
|
</p>
|
|
<p>(−0.04 to 0.04)</p>
|
|
</td><td headers="hd_h_niceng239er7.tab6_1_1_1_5 hd_h_niceng239er7.tab6_1_1_2_1" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">0 per 1,000</td><td headers="hd_h_niceng239er7.tab6_1_1_1_5 hd_h_niceng239er7.tab6_1_1_2_2" rowspan="1" colspan="1" style="text-align:center;vertical-align:middle;">
|
|
<p>
|
|
<b>0 fewer per 1,000</b>
|
|
</p>
|
|
<p>(40 fewer to 40 more)</p>
|
|
</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>a</dt><dd><div id="niceng239er7.tab6_1"><p class="no_margin">Very high risk of bias due to confounding, classification of interventions and missing data</p></div></dd></dl><dl class="bkr_refwrap"><dt>b</dt><dd><div id="niceng239er7.tab6_2"><p class="no_margin">Serious population indirectness due to lack of information reported on previous gastric surgery</p></div></dd></dl><dl class="bkr_refwrap"><dt>c</dt><dd><div id="niceng239er7.tab6_3"><p class="no_margin">Downgraded by 1 increment if the confidence interval crossed one MID and by 2 increments if the confidence interval crossed two MIDs (0.8 and 1.25 for dichotomous outcomes; 0.5 * median of baseline SD of the intervention and control group for continuous outcomes)</p></div></dd></dl><dl class="bkr_refwrap"><dt>d</dt><dd><div id="niceng239er7.tab6_4"><p class="no_margin">Absolute effect calculated using risk difference</p></div></dd></dl><dl class="bkr_refwrap"><dt>e</dt><dd><div id="niceng239er7.tab6_5"><p class="no_margin">Serious imprecision (risk difference and sample size >70<350)</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng239er7tab7"><div id="niceng239er7.tab7" class="table"><h3><span class="label">Table 7</span><span class="title">Health economic evidence profile: Gastroscopy surveillance for people with pernicious anaemia</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.tab7/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.tab7_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_niceng239er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Study</th><th id="hd_h_niceng239er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Applicability</th><th id="hd_h_niceng239er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Limitations</th><th id="hd_h_niceng239er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Other comments</th><th id="hd_h_niceng239er7.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Incremental cost<sup>(c)</sup></th><th id="hd_h_niceng239er7.tab7_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Incremental effects</th><th id="hd_h_niceng239er7.tab7_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Cost effectiveness</th><th id="hd_h_niceng239er7.tab7_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:bottom;">Uncertainty</th></tr></thead><tbody><tr><td headers="hd_h_niceng239er7.tab7_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Lahner 2017<a class="bibr" href="#niceng239er7.s1.1.ref3" rid="niceng239er7.s1.1.ref3"><sup>3</sup></a> (Italy)</td><td headers="hd_h_niceng239er7.tab7_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Partially applicable<sup>(a)</sup></td><td headers="hd_h_niceng239er7.tab7_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Potentially serious limitations<sup>(b)</sup></td><td headers="hd_h_niceng239er7.tab7_1_1_1_4" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<ul><li class="half_rhythm"><div>Simple cost-effectiveness analysis based on cohort from Italy.</div></li><li class="half_rhythm"><div>Population: Pernicious anaemia</div></li><li class="half_rhythm"><div>A) without extensive atrophy (n=79)</div></li><li class="half_rhythm"><div>B) with extensive atrophy (n=23)</div></li></ul>
|
|
<p>Time horizon: 7.5 years (range 4 – 23.4 years)</p></td><td headers="hd_h_niceng239er7.tab7_1_1_1_5" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>A)</dt><dd><p class="no_top_margin">£376</p></dd></dl><dl class="bkr_refwrap"><dt>B)</dt><dd><p class="no_top_margin">£234</p></dd></dl></dl>
|
|
</td><td headers="hd_h_niceng239er7.tab7_1_1_1_6" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>A)</dt><dd><p class="no_top_margin">2/79</p></dd></dl><dl class="bkr_refwrap"><dt>B)</dt><dd><p class="no_top_margin">2/23</p></dd></dl></dl>
|
|
</td><td headers="hd_h_niceng239er7.tab7_1_1_1_7" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
<dl class="temp-labeled-list"><dl class="bkr_refwrap"><dt>A)</dt><dd><p class="no_top_margin">£13,346 per cancer detected</p></dd></dl><dl class="bkr_refwrap"><dt>B)</dt><dd><p class="no_top_margin">£2,692 per cancer detected</p></dd></dl></dl>
|
|
</td><td headers="hd_h_niceng239er7.tab7_1_1_1_8" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">No sensitivity analysis reported.</td></tr></tbody></table></div><div class="tblwrap-foot"><div><dl class="temp-labeled-list small"><dl class="bkr_refwrap"><dt>(a)</dt><dd><div id="niceng239er7.tab7_1"><p class="no_margin">The population included all have pernicious anaemia with an appropriate intervention – gastroscopy as per the protocol. Although the study does not have a UK NHS perspective, the study is conducted in a similar system compared to the NHS and the healthcare perspective used is appropriate. The use of gastroscopy also reflects current practice in the NHS. However, no QALYs reported. Furthermore, discounting is not applied/reported.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(b)</dt><dd><div id="niceng239er7.tab7_2"><p class="no_margin">QALYs are not reported, and health outcomes are not included. The only cost incorporated is gastroscopy, no other costs such as treatment costs are reported or the costs of further investigations such as biopsy. There was no sensitivity analysis conducted. The sample size was small.</p></div></dd></dl><dl class="bkr_refwrap"><dt>(c)</dt><dd><div id="niceng239er7.tab7_3"><p class="no_margin">2017 Italy Euros converted to UK pounds<a class="bibr" href="#niceng239er7.s1.1.ref5" rid="niceng239er7.s1.1.ref5"><sup>5</sup></a>. Cost components incorporated: Gastroscopy.</p></div></dd></dl></dl></div></div></div></article><article data-type="table-wrap" id="figobniceng239er7appjtab1"><div id="niceng239er7.appj.tab1" class="table"><h3><span class="label">Table 13</span><span class="title">Studies excluded from the clinical review</span></h3><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK603289/table/niceng239er7.appj.tab1/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__niceng239er7.appj.tab1_lrgtbl__"><table><thead><tr><th id="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Study</th><th id="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">Code [Reason]</th></tr></thead><tbody><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Affronti, J and Baillie, J (1994) Gastroscopic follow-up of pernicious anemia patients. Gastrointestinal endoscopy
|
|
40(1): 129
|
|
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/8163130" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8163130</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Anonymous. (1998) The role of endoscopy in the surveillance of premalignant conditions of the upper gastrointestinal tract. Gastrointestinal Endoscopy
|
|
48(6): 663–668
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9852468" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9852468</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Guideline</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Arvanitakis, C.; Holmes, F.F.; Hearne
|
|
III, E. (1979) A possible association of pernicious anemia with neoplasia. Oncology
|
|
36(3): 127–129
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/471423" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 471423</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Banks, Matthew, Graham, David, Jansen, Marnix
|
|
et al. (2019) British Society of Gastroenterology guidelines on the diagnosis and management of patients at risk of gastric adenocarcinoma. Gut
|
|
68(9): 1545–1575
|
|
[<a href="/pmc/articles/PMC6709778/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC6709778</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31278206" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 31278206</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Guideline</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
BIRD, R M (1953) Detection of carcinoma of the stomach in patients with pernicious anemia. Southern medical journal
|
|
46(5): 434–9
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/13056789" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 13056789</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
BOON, T H, SCHADE, R O, MIDDLETON, G D
|
|
et al. (1964) AN ATTEMPT AT PRESYMPTOMATIC DIAGNOSIS OF GASTRIC CARCINOMA IN PERNICIOUS ANAEMIA. Gut
|
|
5: 269–70
|
|
[<a href="/pmc/articles/PMC1552122/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1552122</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/14178714" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14178714</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Borch, K (1986) Epidemiologic, clinicopathologic, and economic aspects of gastroscopic screening of patients with pernicious anemia. Scandinavian journal of gastroenterology
|
|
21(1): 21–30
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/3952448" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 3952448</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Data not reported in an extractable format or a format that can be analysed</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Borch, K and Liedberg, G (1984) Prevalence and incidence of pernicious anemia. An evaluation for gastric screening. Scandinavian journal of gastroenterology
|
|
19(2): 154–60
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/6719030" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6719030</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Bresky, G, Mata, A, Llach, J
|
|
et al. (2003) Endoscopic findings in a biennial follow-up program in patients with pernicious anemia. Hepato-gastroenterology
|
|
50(54): 2264–6
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/14696513" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 14696513</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Brinton, L A, Gridley, G, Hrubec, Z
|
|
et al. (1989) Cancer risk following pernicious anaemia. British journal of cancer
|
|
59(5): 810–3
|
|
[<a href="/pmc/articles/PMC2247229/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC2247229</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2736218" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 2736218</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Elsborg, L; Andersen, D; Bastrup-Madsen, P (1973) Gastrocamera screening in pernicious anaemia. With special reference to the occurrence of gastric polyps and cancer. Scandinavian journal of gastroenterology
|
|
8(1): 5–8
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/4697066" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4697066</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Elsborg, L, Andersen, D, Myhere-Jensen, O
|
|
et al. (1977) Gastric mucosal polyps in pernicious anaemia. Scandinavian journal of gastroenterology
|
|
12(1): 49–52
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/65002" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 65002</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hsing, A W, Hansson, L E, McLaughlin, J K
|
|
et al. (1993) Pernicious anemia and subsequent cancer. A population-based cohort study. Cancer
|
|
71(3): 745–50
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/8431855" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8431855</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Hughes, Jing W, Muegge, Brian D, Tobin, Garry S
|
|
et al. (2017) HIGH-RISK GASTRIC PATHOLOGY AND PREVALENT AUTOIMMUNE DISEASES IN PATIENTS WITH PERNICIOUS ANEMIA. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
|
|
23(11): 1297–1303
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/29190137" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 29190137</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Jordan, Paul H
|
|
Jr; Barroso, Alberto; Sweeney, John (2004) Gastric carcinoids in patients with hypergastrinemia. Journal of the American College of Surgeons
|
|
199(4): 552–5
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/15454137" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 15454137</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Kokkola, A, Sjoblom, S M, Haapiainen, R
|
|
et al. (1998) The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scandinavian journal of gastroenterology
|
|
33(1): 88–92
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/9489914" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 9489914</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lahner, Edith, Hassan, Cesare, Esposito, Gianluca
|
|
et al. (2017) Cost of detecting gastric neoplasia by surveillance endoscopy in atrophic gastritis in Italy: A low risk country. Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver
|
|
49(3): 291–296
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/28034664" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 28034664</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Lehtola, J.; Karttunen, T.; Krekela, I. (1985) Gastric carcinoids with minimal or no macroscopic lesion in patients with pernicious anemia. Hepato-Gastroenterology
|
|
32(2): 72–76
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/4007765" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4007765</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Schafer, L W, Larson, D E, Melton, L J
|
|
3rd
|
|
et al. (1985) Risk of development of gastric carcinoma in patients with pernicious anemia: a population-based study in Rochester, Minnesota. Mayo Clinic proceedings
|
|
60(7): 444–8
|
|
[<a href="https://pubmed.ncbi.nlm.nih.gov/4010342" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 4010342</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sjoblom, S M; Sipponen, P; Jarvinen, H (1993) Gastroscopic follow up of pernicious anaemia patients. Gut
|
|
34(1): 28–32
|
|
[<a href="/pmc/articles/PMC1374095/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1374095</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8432447" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8432447</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Duplicate reference</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Sjoblom, S.M.; Sipponen, P.; Jarvinen, H. (1993) Gastroscopic follow up of pernicious anaemia patients. Gut
|
|
34(1): 28–32
|
|
[<a href="/pmc/articles/PMC1374095/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1374095</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8432447" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 8432447</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Review article but not a systematic review</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Stockbrugger, R W, Menon, G G, Beilby, J O
|
|
et al. (1983) Gastroscopic screening in 80 patients with pernicious anaemia. Gut
|
|
24(12): 1141–7
|
|
[<a href="/pmc/articles/PMC1420244/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1420244</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/6642278" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 6642278</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr><tr><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
|
|
Ye, W and Nyren, O (2003) Risk of cancers of the oesophagus and stomach by histology or subsite in patients hospitalised for pernicious anaemia. Gut
|
|
52(7): 938–41
|
|
[<a href="/pmc/articles/PMC1773712/" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pmc">PMC free article<span class="bk_prnt">: PMC1773712</span></a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/12801947" ref="pagearea=body&targetsite=entrez&targetcat=link&targettype=pubmed">PubMed<span class="bk_prnt">: 12801947</span></a>]
|
|
</td><td headers="hd_h_niceng239er7.appj.tab1_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">- Study design not relevant to this review protocol</td></tr></tbody></table></div></div></article></div><div id="jr-scripts"><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/libs.min.js"> </script><script src="/corehtml/pmc/jatsreader/ptpmc_3.22/js/jr.min.js"> </script></div></div>
|
|
|
|
|
|
|
|
|
|
<!-- Book content -->
|
|
|
|
<script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js"> </script>
|
|
|
|
|
|
<!-- CE8B5AF87C7FFCB1_0191SID /projects/books/PBooks@9.11 portal104 v4.1.r689238 Tue, Oct 22 2024 16:10:51 -->
|
|
<span id="portal-csrf-token" style="display:none" data-token="CE8B5AF87C7FFCB1_0191SID"></span>
|
|
|
|
<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4216699/js/3968615.js" snapshot="books"></script></body>
|
|
</html>
|